Treating Acute Leukemias in
Japan and the Asia-Pacific Region

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases

Overview

This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.

Date and Location

August 22–23, 2024; Webinar

  • Tokyo – 9:00 am – 12:00 pm​
  • Beijing/Singapore – 8:00 am – 11:00 am

Meeting Content

Co-Chairs

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Naval Daver

Naval Daver, MD

MD Anderson Cancer Center, Houston, TX, USA

Faculty

Daniel DeAngelo

Daniel J. DeAngelo, MD, PhD

Harvard Medical School, Boston, MA, USA

Jae Park

Jae Park, MD

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Shaun Fleming

Shaun Fleming, MBBS(Hons), FRACP, FRCPA

Melbourne Haematology, Richmond, VIC, Australia

Agenda

This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within the Asia-Pacific region.

Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the Asia-Pacific region.

Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment.

Day 1 – PLENARY SESSIONS

Sunday, September 10, 2023

8.00 AM – 11.00 AM (UTC +8) Shanghai
9.00 AM – 12.00 PM (UTC +9) Tokyo
10.00 AM – 1.00 PM (UTC +10) Sydney

Time (UTC +8) Topic Presenter
8.00 AM
8.10 AM
Welcome and meeting overview Elias Jabbour
8.10 AM
8.25 AM
Review of prognostic value of MRD in ALL and AML Jae Park
8.25 AM
8.40 AM
Latest achievements and developments in ALL and AML Elias Jabbour
8.40 AM
8.55 AM
Genetic characterization and risk stratification of AML Daniel DeAngelo
8.55 AM
9.25 AM

ALL case-based panel discussion

  • Case ALL (10 min) – fellow (TBD)
  • Case AYA ALL (10 min) – fellow (TBD)
  • Discussion (10 min) – panelists: all faculty
Elias Jabbour and all faculty
9.25 AM
9.35 AM
Break  
9.35 AM
9.50 AM
Therapeutic approaches in high-risk and frail AML patients Naval Daver
9.50 AM
10.05 AM
Current approach to maintenance strategies in ALL and AML Jae Park
10.05 AM
10.20 AM
Long-term safety considerations in AML Shaun Fleming
10.20 AM
10.50 AM
Panel discussion: Open questions in ALL and AML – regional specificities Elias Jabbour and all faculty
10.50 AM
11.00 AM
Session close Elias Jabbour

Day 2 – Plenary Sessions

Monday, September 11, 2023

8.00 AM – 11.00 AM (UTC +8) Shanghai
9.00 AM – 12.00 PM (UTC +9) Tokyo
10.00 AM – 1.00 PM (UTC +10) Sydney

Time (UTC +8) Topic Presenter
8.00 AM
8.10 AM
Welcome to Day 2 Elias Jabbour
8.10 AM
8.30 AM
Current treatment options for relapsed ALL in adult and elderly patients Elias Jabbour
8.30 AM
8.50 AM
Current treatment options for relapsed AML in adult and elderly patients Junichuro Yuda
8.50 AM
9.20 AM

Case-based panel discussion

  • Case AML (10 min) – fellow (TBD)
  • Case ALL, high risk or elderly (10 min) – fellow (TBD)
  • Discussion (10 min) – panelists: all faculty
Naval Daver and all faculty
9.20 AM
9.30 AM
Break  
9.30 AM
9.50 AM
AYA ALL patients: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Daniel DeAngelo
9.50 AM
10.20 AM

Current and future role of transplantation in acute leukemias

  • Jae Park (in general) (10 min)
  • Shaun Fleming (in the JAPAC region) (10 min)
  • Discussion (10 min)
Jae Park/Shaun Fleming
10.20 AM
10.50 AM

Panel discussion: How treatment in first line influences further approaches in ALL and AML

  • Will CAR T and bispecifics change the landscape?
  • Role of HSCT – is it still confirmed?
  • What does the future look like?
Elias Jabbour and all faculty
10.50 AM
11.00 AM
Session close Elias Jabbour